Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619532 | 0.78 | — | — | |
| SCHEMBL20871750 | 0.75 | ALDH1A1 (0.36) | — | |
| SCHEMBL2026471 | 0.74 | ALOX15 (0.34) | ALOX15 | |
| SCHEMBL1187971 | 0.71 | ALDH1A1 (0.47) | ALOX15 | |
| SCHEMBL21342599 | 0.71 | ALDH1A1 (0.33) | — | |
| SCHEMBL14459682 | 0.67 | — | — | |
| SCHEMBL14458319 | 0.64 | LMNA (0.32) | — | |
| SCHEMBL8849510 | 0.60 | ALDH1A1 (0.42) | — | |
| SCHEMBL5144912 | 0.60 | IDO1 (0.46) | ALOX15 | |
| SCHEMBL5587085 | 0.59 | CES2 (0.41) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332534-B1 | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers | BIOELECTRON TECH CORP (US) | 2018-11-14 | — | — | EP | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| EP-2617418-B1 | PHENOL AND 1,4-BENZOQUINONE DERIVATIVES FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECH CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20160244392-A1 | SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS, INC. | 2016-08-25 | — | — | US | disclosed |
| US-9278085-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2617418-A1 | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | Edison Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2617417-A1 | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | Edison Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1986636-B1 | PHENOL AND 1,4-BENZOQUINONE DERIVATIVES FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS INC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2332534-A1 | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers | Edison Pharmaceuticals, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-1986636-A2 | SIDE CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | Edison Pharmaceuticals, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007100652-A2 | SIDE CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244392-A1 | SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | FH, NDUFAB1, ACAA2 | ALOX15 420/4885 |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | FH, NDUFAB1, ACAA2 | ALOX15 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.